Product Name: CDNF Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, IF, IHC-P, WB
Applications: CDNF antibody can be used for detection of CDNF by Western blot at 2 – 4 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: CDNF antibody was raised against a 9 amino acid synthetic peptide from near the carboxy terminus of human CDNF.The immunogen is located within the last 50 amino acids of CDNF.
Host Species: Rabbit
Purification: CDNF Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 57808-66-9
Product: Domperidone
Buffer: CDNF Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: CDNF antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: CDNF Antibody: ARMETL1, ARMETL1, Cerebral dopamine neurotrophic factor, ARMET-like protein 1
Accession NO.: Q49AH0
Protein Ino: 143955278
Official Symbol: ARMETL1
Geneid: 441549
Background: CDNF Antibody: The conserved dopamine neurotrophic factor (CDNF) is a neurotrophic factor for dopaminergic neurons and highly homologous to the mesencephalic-astrocyte-derived neuro-trophic factor. Somewhat surprisingly, CDCF is expressed at higher levels in tissues such as heart, skeletal muscle and testes than in brain. Similar to the glial cell line-derived neurotrophic factor (GDNF), CDNF can prevent the 6-hydroxylamine (6-OHDA)-induced degeneration of dopaminergic neurons in a rat model of Parkinsons disease. Furthermore, CDNF was able to restore the dopaminergic function and prevent the degeneration of dopaminergic neurons in the substantia nigra, suggesting that CDNF might be suitable for the treatment of Parkinsons disease. At least two isoforms of CDNF are known to exist.
PubMed ID:http://aac.asm.org/content/35/9/1840.abstract
